VERZENIO
PeakNDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERZENIO is an oral small-molecule drug approved by FDA in February 2018 for an unknown indication. The exact mechanism of action and therapeutic area cannot be determined from available data, but the product is currently in peak commercial lifecycle stage.
$757MPart D
PeakPeak lifecycle status with $757M in Part D spending indicates a mature, established commercial franchise with stable sales team and supporting infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast
Started Mar 2022
1,500 enrolled
The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
Why This Matters for Your Career
Worked on VERZENIO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.